Effects of Teneligliptin improvement endotherial dysfunction, inflammation, coagulation and oxidative stress in patients with coronary artery disease and diabetes, pilot study(Tiramisu study).
Not Applicable
Completed
- Conditions
- Coronary artery disease
- Registration Number
- JPRN-UMIN000011960
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Type I diabetes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of endothelial function
- Secondary Outcome Measures
Name Time Method HbA1c,Glycated albumin,1.5-anhydro-D-glucitol,fasting plasma glucose, immunoreactive insulin, HOMA-IR, HOMA-beta, hs-CRP, IL-6, MCP-1, TNF-alpha Red blood cell, White blood cell, platelet, D dimer, FDP, fibrinogen, 8-OHdG, BNP, body weight
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Teneligliptin's DPP-4 inhibition mechanism improve endothelial dysfunction and oxidative stress in diabetic coronary artery disease patients?
What is the comparative effectiveness of Teneligliptin versus standard-of-care DPP-4 inhibitors in managing inflammation and coagulation in CAD-diabetes comorbidity?
Which biomarkers correlate with Teneligliptin's therapeutic response in coronary artery disease patients with type 2 diabetes mellitus?
What are the cardiovascular safety profiles and adverse event management strategies for Teneligliptin in patients with atherosclerotic CAD and hyperglycemia?
How does Teneligliptin's anti-inflammatory effect compare to GLP-1 receptor agonists in improving endothelial function in diabetic coronary artery disease?